TNFα antagonist continuation rates in 442 patients with inflammatory joint disease
- 31 March 2007
- journal article
- Published by Elsevier in Joint Bone Spine
- Vol. 74 (2), 148-154
- https://doi.org/10.1016/j.jbspin.2006.06.011
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the communityJoint Bone Spine, 2006
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis & Rheumatism, 2004
- Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor blockers can make senseAnnals Of The Rheumatic Diseases, 2003
- Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot studyClinical Therapeutics, 2003
- Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trialThe Lancet, 2002
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984